Clinical Trial Update: An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin [Phase 1]

View source ↗

Summary

An open-label Phase 1 pilot study evaluated biomarker responses after short-term exposure to metformin in colorectal cancer; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Carcinoma | Phase 1 | Status: TERMINATED